abstract |
To provide a stable pharmaceutical preparation containing a monoclonal antibody. Antibodies including monoclonal antibodies formulated in histidine-acetate buffer, as well as formulations containing antibodies that bind to domain II of HER2 (eg, pertuzumab) and formulations that contain antibodies that bind to DR5 (eg, Apomab) Formulation. [Selection figure] None |